| Literature DB >> 34948277 |
Boris V Chernyak1, Konstantin G Lyamzaev1, Armen Y Mulkidjanian1,2,3.
Abstract
In humans, over-activation of innate immunity in response to viral or bacterial infections often causes severe illness and death. Furthermore, similar mechanisms related to innate immunity can cause pathogenesis and death in sepsis, massive trauma (including surgery and burns), ischemia/reperfusion, some toxic lesions, and viral infections including COVID-19. Based on the reviewed observations, we suggest that such severe outcomes may be manifestations of a controlled suicidal strategy protecting the entire population from the spread of pathogens and from dangerous pathologies rather than an aberrant hyperstimulation of defense responses. We argue that innate immunity may be involved in the implementation of an altruistic programmed death of an organism aimed at increasing the well-being of the whole community. We discuss possible ways to suppress this atavistic program by interfering with innate immunity and suggest that combating this program should be a major goal of future medicine.Entities:
Keywords: COVID-19; damage-associated molecular patterns (DAMPs); inflammasome; inflammation; mitochondrially-targeted antioxidants; pathogen-associated molecular patterns (PAMPs); phenoptosis; programmed death
Mesh:
Substances:
Year: 2021 PMID: 34948277 PMCID: PMC8704876 DOI: 10.3390/ijms222413480
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Release mechanisms for some DAMPs. High-mobility group protein B1 (HMGB1) and cold-inducible RNA-binding protein (CIRP) are released from the nucleus after modification to be entrapped and secreted by secretory lysosomes (which are produced by the trans-Golgi network). Interleukins 1a and 33 (IL1a, IL33) are also secreted by secretory lysosomes, but may be also released through the pores formed by gasdermin D (GSDMD). Mitochondria, after fragmentation, can be extruded from cells by an unknown mechanism(s). Secretory granules, as produced by the trans-Golgi network, release defensins and eosinophil-derived neurotoxin (EDN) by exocytosis. ATP is released through the pore formed by pannexin I complexed with the purinergic receptor P2X7. Sequestosome-1 (SQSTM1/h62) is an autophagosome receptor that can be released during secretory autophagy.
Typical damage-associated molecular patterns (DAMPs).
| # | Origin | DAMPs | Receptors | Ref |
|---|---|---|---|---|
| 1 | Nucleus | HMGB1 | TLR2, TLR4, RAGE | [ |
| CIRP | TLR4, TREM-1 | [ | ||
| Histones | TLR2, TLR4 | [ | ||
| SAP130 | Mincle | [ | ||
| IL-1α | IL1R1 | [ | ||
| IL-33 | ST2 | [ | ||
| DNA | cGAS, AIM2, RAGE, IFI16 | [ | ||
| 2 | Cytosol | S100 proteins | TLR2, TLR4, RAGE | [ |
| HSPs | TLR2, TLR4, CD91 | [ | ||
| F-Actin | DNGR-1, TREM1 | [ | ||
| Cyclophilin A | CD147 | [ | ||
| Peroxiredoxin 1 | TLR4 | [ | ||
| Oxidized hemoglobin, heme | TLR4 | [ | ||
| Amyloid β | TLR4 | [ | ||
| ATP, ADP | P2X7R, P2Y2R, P2Y12R, | [ | ||
| Uric acid | TREM-1, TLR2, TLR4, P2X7, NLRP3 | [ | ||
| mRNA | TLR3 | [ | ||
| microRNAs | TLR7 | [ | ||
| SNAPIN | TLR2 | [ | ||
| AGEs | RAGE | [ | ||
| 3 | Mitochondria | Formyl peptides | FPR1 | [ |
| mtDNA | TLR9, NLRP3 | [ | ||
| Cardiolipin | NLRP3, TREM2 | [ | ||
| Cytochrome | TLR4 | [ | ||
| Oxygenated mitochondrial fatty acids | TRL4 | [ | ||
| TFAM | RAGE | [ | ||
| 4 | ER, secretory granules, autophagosomes | Defensins | TLR4 | [ |
| Cathelicidins | P2X7, FPR2 | [ | ||
| Eosinophil-derived neurotoxin | TLR2 | [ | ||
| Granulisin | TLR4 | [ | ||
| Calreticulin | CD91 | [ | ||
| Gp96 | TLR2, TLR4, CD91 | [ | ||
| Sequestosome-1 (SQSTM1 or p62) | INSR | [ | ||
| 5 | Extracellular matrix | Heparan sulphate, versican, aggrecan | TLR4 | [ |
| Proteoglycans (biglycan, decorin, etc.) | TLR2, TLR4, CD14, NLRP3 | [ | ||
| Tenascin-C | TLR4 | [ | ||
| Fibrinogen | TLR4 | [ | ||
| Fibronectin | TLR2, TLR4 | [ | ||
| Low molecular weight hyaluronan | TLR2, TLR4, NLRP3 | [ | ||
| 6 | Tumor cells | Annexin A1 | FPR1 | [ |
| PAUF | TLR4 | [ | ||
| API5 | TLR4 | [ | ||
| Rps-3 | TLR4 | [ |
Abbreviations: AGEs, advanced glycation end products; AIM2, absent in melanoma 2;API5, apoptosis inhibitor 5; cGAS, cyclic GMP-AMP synthase; CIRP, cold-inducible RNA-binding protein; DNGR1, dendritic cell natural killer lectin group receptor 1; FPR1, Formyl peptide receptor 1; HMGB1, high mobility group box-1 protein; HSPs, heat shock proteins; INSR, insulin receptor; Mincle, macrophage inducible Ca2+-dependent lectin receptor; NLRP3, NLR family pyrin domain containing 3; P2X7R, P2X7 receptor; P2Y2R, P2Y2 receptor; PAUF, pancreatic adenocarcinoma up-regulated factor; RAGE, receptor for advanced glycation end products; Rps-3, 40S ribosomal protein S3; SAP130, Sin3A Associated Protein 130; SNAPIN, SNARE-associated protein Snapin; ST2, Suppression of tumorigenicity 2 receptor; TFAM, mitochondrial transcription factor A; TLRs, Toll- like receptors; TREM1, triggering receptors expressed on myeloid cells 1.
Figure 2Main DAMP-sensing receptors and signaling. DAMPs can be recognized by membrane receptors, such as Toll- like receptors (TLRs), receptor for advanced glycation end products (RAGE), triggering receptor expressed on myeloid cells 1 (TREM-1), formyl peptide receptors (FPRs), C-type lectin receptors (CLRs), purinergic receptor P2X7, as well as by cytoplasmic receptors such as cyclic GMP-AMP synthase (cGAS) and NLR family pyrin domain containing 3 (NLRP3) inflammasome. Endogenous nuclear and mitochondrial DNA released into the cytoplasm activate cGAS, which produces cyclic GMP-AMP (cGAMP) that binds to stimulator of interferon genes (STING). Activated STING stimulates the kinases TBK1 and IKK, leading to the expression of type-I interferons (IFN-I) and inflammatory cytokines. TLR2 and TLR4 can be activated by a variety of extracellular DAMPs, whereas TLRs 3, 7, and 9 are activated by phagocytosed nucleic acids in endosomes. TLR-dependent signaling is mediated by the adaptor proteins: myeloid differentiation primary-response 88 (MyD88), and TIR-domain-containing adaptor inducing IFNβ (TRIF). The both adaptors activate mitogen-activated protein kinases (MAPKs) and IκB kinase (IKK), leading to activation of the transcription factors activator protein 1 (AP-1) and nuclear factor κB (NFκB), which stimulate the expression of inflammatory cytokines. TRIF also activates TANK binding kinase 1 (TBK1), which activates the interferon regulatory factors (IRFs) leading to the expression of type I interferon (IFN-I). RAGEs, which recognize HMGB1, S100 and some other DAMPs, also activate MyD88. TREM-1, which recognizes CIRP, activates spleen tyrosine kinase (SYK), that further stimulates MyD88, MAPKs and NFκB. Several C-type lectin receptors (CLRs) recognize F-actin and SAP130 and also activate SYK. Formyl peptide receptors (FPRs) are G-protein coupled receptors that recognize mitochondrial N-formylated peptides and stimulate several signaling pathways (including MAPKs) to activate neutrophils. P2X7 is ionotropic receptor that opens Ca2+ channel in response to extracellular ATP. An increase in the concentration of Ca2+ in cytoplasm modulates various signaling pathways and stimulates the production of reactive oxygen species (ROS) in mitochondria. Elevated ROS levels are critical for the activation of MAPKs, NFκB and the NLRP3 inflammasome. ROS-oxidized mitochondrial DNA is recognized by NLRP3.
Figure 3Scheme of the induction of phenoptosis in bacterial sepsis. This scheme can also be applied to pathologies associated with aseptic inflammation.